Pricing Log in Create free account

Climb Bio, Inc. (CLYM) vs Prime Medicine, Inc. (PRME)

Climb Bio, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Climb Bio, Inc. and Prime Medicine, Inc. are of similar size ($654.8M and $626.6M). Climb Bio, Inc. has the higher net margin (0.00% vs −4,613.1%) and the lower return on invested capital (−71.7% vs 0.00%). Across the 12 metrics below, Climb Bio, Inc. leads on 10 and Prime Medicine, Inc. on 2.

Valuation

Metric CLYM PRME Biotechnology median
P/E n/m n/m 8.50
P/S n/m 150.99 9.71
P/B 3.12 15.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 127.65 9.21
Earnings yield (8.45%) (30.93%) (33.15%)
Free cash flow yield (7.11%) (25.50%) (25.50%)

Profitability

Metric CLYM PRME Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (4,824.94%) 0.00%
Net margin 0.00% (4,613.11%) 0.00%
Free cash flow margin 0.00% (3,850.92%) 0.00%
Return on equity (27.10%) (373.29%) (56.36%)
Return on assets (26.27%) (71.16%) (48.04%)
Return on invested capital (71.73%) 0.00% 0.00%

Growth

Metric CLYM PRME Biotechnology median
Revenue growth (TTM) — (17.90%) 6.02%
EPS growth (last fiscal year) 42.48% 18.18% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLYM PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 31.45 3.05 4.72
Net debt to EBITDA 1.44 0.88 0.96

Dividend

Metric CLYM PRME Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CLYM PRME Biotechnology median
Market cap 626.63m 654.77m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack